Keith Regnante sold $1.8M of Keros Therapeutics (KROS)

Executed Jan 4 2024, disclosed Jan 24 2025, 386 days later, against a two-business-day limit.

Value, as filed

$1.8M

40,000 sh × $45.29

Executed

Jan 4 2024

the trade date, as filed

Disclosed

Jan 24 2025

386 days after the trade · past the deadline

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

KR Keith Regnante CHIEF FINANCIAL OFFICER profile →

Keith Regnante (CHIEF FINANCIAL OFFICER) filed 1 Form 4 report in the past 24 months (0 purchases, 1 sale, 1 filed past the two-business-day deadline), most often in KROS.

The name

KROS KROS KROS · 5 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→